Patient-partnered look at fear of cancer returning after kidney cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project forms a panel of Danish-speaking patients treated surgically for localized renal cell carcinoma (T1–T3) and their partners to co-design which questions, formats, and timings best capture Fear of Cancer Recurrence (FCR) in follow-up care. Investigators will use the 42-item Fear of Cancer Recurrence Inventory (FCRI) for inspiration, translate a caregiver version into Danish, and hold online or in-person meetings to produce recommendations. In a pilot feasibility phase the team will test the recommended questions, modes (digital or in-clinic), and timing with patients and partners to collect real-world FCR data after surgery. Sites include Gødstrup, Aalborg, and Aarhus University Hospitals and outcomes focus on feasibility, acceptability, and preliminary FCR levels.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Phase 1:

* Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner/spouse
* Partner/spouse to patients who fullfil the inclusion criteria
* Patients have undergone surgery due to localized RCC (T1-T2-T3 tumor)
* Time since surgery: 0-120 months
* Danish speaking patients and partners/spouses. Must be able to speak, write and read Danish
* Patients/partners/spouses able to and willing to attend online project meetings or in person at Gødstrup Hospital.

Phase 2:

* Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner/spouse
* Partner/spouse to patients who fullfill the inclusion criteria
* Patients who have undergone surgery due to localized RCC (T1-T2-T3 tumor)
* Danish speaking patients and partners/spouses. Must be able to speak, write and read Danish
* Able to receive digital communication from the hospital
* Informed consent must be signed before answering Fear of Cancer Recurrence questions

Exclusion Criteria:

Both phases, both patients and partners/spouses:

* Diagnosed with cognitive impairment
* Untreated psychiatric disorders due to non-compliance

Phase 2:

• Patients and partners/spouses who were panelists in phase 1

Where it's running

• Aalborg University Hospital
  Aalborg, Denmark Recruiting
• Aarhus University Hospital
  Aarhus, Denmark Recruiting
• Gødstrup Hospital
  Herning, Denmark Recruiting

Study contacts

• Study coordinator: Brigitta R Villumsen, PhD
• Email: brigvill@rm.dk
• Phone: +45 20487820

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• QLESP Block to Ease Pain After Robot-Assisted Kidney Surgery

  Doctors are testing a ultrasound-guided nerve block called QLESP to see if it lowers pain and reduces strong pain medicines after robotic partial nephrectomy in adults.

  Recruiting Huazhong University of Science and Technology · Wuhan, Hubei · NCT07704970

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Bone density changes with anti-PD-1 immunotherapy

  This pilot will test if anti-PD-1 immunotherapy changes bone density in adults starting approved anti-PD-1 treatment for certain early-stage cancers.

  Recruiting Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07555210

• Galectin-3 levels and outcomes with PD-1/PD-L1 therapy in kidney, bladder, lung, and liver cancer

  This study tests whether blood galectin‑3 levels before treatment predict outcomes for people with kidney, bladder, lung, or liver cancer who are starting PD‑1/PD‑L1 immunotherapy.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv, Israel · NCT07485114

• Template lymph node surgery plus kidney removal vs kidney removal alone for high-risk kidney cancer

  In people with high-risk kidney cancer, this study tests whether removing a broader set of lymph nodes during kidney removal helps people live longer and have their cancer stay away longer compared with removing only a few affected nodes.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07321197

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.